Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal for you to read. Along with our medical data and news we also list Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Companies for you to search.
(MedPage Today) -- Patients used antiseptic soap, mouthwash, nasal ointment for 6 months
An experimental nasal spray developed by Johnson & Johnson to treat depression could be headed for FDA approval.
Two FDA panels jointly recommended esketamine 28-mg single-use nasal spray for the patients with treatment-resistant depression. News Alerts
Soleo’s Marum GENtLE THERAPY Shampoo, marketed as an anti-dandruff and hair-growth treatment, is an unapproved new drug, according to FDA...
– Grew 2018 revenue 16% year-over-year to $347 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million – – Progressed separation of Ironwood and Cyclerion into two publicly-traded companies with completion expected first half 2019 – – Advance...
Science blog With our appetite for low or zero sugar products increasing, artificial sweeteners are big business. Food or drinks containing artificial sweeteners are often marketed as a healthier option, and it’s understandable why. Because artificial sweeteners are significantly sweeter than sugar, they can be used in very small amounts and contribute little to no calories. There are lots of...
A panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal spray for depression, esketamine, bringing the medicine closer to approval. Votes from the FDA’s panel are not binding, but the regulator us...
In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine nasal spray Spravato has been recommended by the FDA’s Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee for the treatment of treatment-resistant depression. The panel voted overwhelmingly in favour of the drug, with 14...
FDA advisory committees have jointly voted in favour of approving Janssen's Spravato nasal spray CIII for adults living with treatment-resistant depression.
FDA grants Fast Track Designation to help expedite the review and approval of drugs in development that treat serious or life threatening diseases and fill an unmet medical need. MMJ International Holdings will be one of the world’s first natural plant-derived cannabinoid prescription drugs once approved by the FDA for the treatment of spasticity and pain due to multiple sclerosis. RESTON, Va. (...
There is little to no evidence that two surgical procedures used to fuse crumbled vertebrae after a spinal fracture caused by osteoporosis reduce pain any better than non-surgical or placebo procedures, according to a new report in the Journal of Bone and Mineral Research. The task force looked into the most commonly used procedures to […] The post Spinal fusion procedures questioned by glob...
Janssen Pharmaceutical has secured recommendation from the US Food and Drug Administration (FDA) advisory committees for the approval of its...Read More... The post FDA panel supports Janssen’s esketamine nasal spray for depression appeared first on Pharmaceutical Technology.
On Tuesday, a U.S. Food and Drug Administration advisory panel overwhelmingly supported approval of the nasal spray treatment.
Experimental nasal spray is intended for people with severe depression who aren't helped by other treatments or therapies.
An advisory panel to the U.S. Food and Drug Administration on Tuesday voted in favor of Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, bringing the drug closer to approval.
- Total Revenue of $228.6 million for the Fourth Quarter of 2018, $853.8 million for the Full Year 2018 - - Cabozantinib Franchise Net Product Revenue of $176.2 million for the Fourth Quarter of 2018, $619.3 million for the Full Year 2018 - - GAAP Diluted EPS of $1.15 for the Fourth Quarter of 2018, $2.21 for the Full Year 2018 - ...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today has closed its previously announced underwritten public offering of 3,950,000 shares of common stock at an offering price of $1.40 per sh...
Interim data show vaccination with mRNA-1653 boosted serum neutralization titers against hMPV and PIV3 at all dose levels tested and was generally well tolerated Company plans to advance mRNA-1653 into a Phase 1b study in seropositive pediatric subjects Conference call to be held at 5:00 p.m. ET today Moderna, Inc., (Nasdaq: MR...
An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.
(MedPage Today) -- Fast-acting nasal spray wins overwhelming support
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepat...